



Oxetanyl Peptides: Novel Peptidomimetic Modules for Medicinal Chemistry

Martin McLaughlin, Ryo Yazaki, Thomas C. Fessard, and Erick M. Carreira*


Department of Chemistry and Applied Biosciences, Laboratorium für Organische Chemie, Vladimir-Prelog-Weg 3, Eidgenössische Technische Hochschule Zürich, CH-8093 Zürich, Switzerland


Supporting Information


ABSTRACT: The synthesis of novel oxetanyl peptides, where the amide bond is replaced by a non-hydrolyzable oxetanylamine fragment, is reported. This new class of pseudodipeptides with the same H-bond donor/acceptor pattern found in proteins expands the repertoire of peptidomimetics.

With over 50 marketed drugs and an estimated \$13 billion market in 2010, peptide drugs are important players in pharmaceuticals.¹ This is however, a relatively small share of the total pharmaceuticals market given the broad range of biological activities displayed by this class of compounds. The discrepancy arises from some inherent limitations of peptides in the drug development process,^{1a,2} including short lifetimes in the stomach, intestine, and plasma, which often result in less than optimal pharmacokinetic profiles. However, the high specificity and potency as well as low toxicity of certain peptides along with advances in drug delivery have led to a renaissance.³

Thus, there are currently dozens of peptide drugs in clinical development in a broad range of therapeutic areas.⁴ As part of our ongoing interest in new building blocks for medicinal chemistry, we report herein a novel approach based upon the use of a 3-amino oxetane as a surrogate for a peptide bond (Figure 1a). The strategy aims at expanding the scope of peptidomimetics that display H-bond donor/acceptor patterns analogous to that of the parent amide bonds, without attendant







susceptibility to enzymatic amide bond cleavage at the site of substitution (Figure 1b).

Peptidomimicry has long sought to provide alternative structural building blocks for fragments or the whole of biologically relevant peptides in an effort to generate compounds with improved pharmacokinetic profiles. A number of creative approaches have been demonstrated including β -peptides and δ -peptide oligomers, peptoids, alkene isosteres, and oligo *o*-substituted aromatics,⁵ and expanding the portfolio of peptidomimetics is of continued interest in drug discovery.

In previous work we have suggested that 3,3-disubstituted oxetanes can be perceived as useful surrogates for carbonyl groups in small heterocycles, leading to analogs of lactams and ketones with improved physico-chemical properties.⁶ Because a primary pathway for degradation of peptides is amide bond hydrolysis, we reasoned that replacement of the amide carbonyl by an oxetane would result in a fragment with increased stability while at the same time give access to novel regions of chemical space. We aimed at developing a strategy for the use of oxetanyl peptides compatible with modern practices in peptide synthesis.⁷ Two strategies were considered for their preparation, which differ in the tactics employed to introduce the amino oxetane residues (Figure 1c).

The first approach (A) would utilize monomeric oxetanyl building blocks while the second (B) would rely on the use of prefabricated dipeptides with embedded oxetanes. Although the former parallels standard peptide synthesis methods, it would require optimization of the coupling conditions for each fragment. In approach **B** the coupling reactions leading to chain extension involve amide bond formation. In either case, the synthetic challenges include the identification of suitable reactions for the preparation of the building blocks and compatible coupling conditions for their incorporation into larger peptides without suffering unwanted side reactions.

 Received:
 June 3, 2014

 Published:
 July 28, 2014

In the initial design of the approach toward surrogate dipeptides (approach **B** in Figure 1c), we favored the 1,4-addition of amino acids to oxetanyl-substituted nitroolefins. Subsequent NO₂-group reduction would lead to terminal primary amines. We first examined the synthesis of dimers $(H_2NAA_{ox}^1-AA^2CO_2H)$ incorporating the glycine surrogate in position AA_{ox}^1 (Table 1). In practice, simple mixing of 1 and H-

Table 1. Synthesis of Dipeptides with Oxetanyl Glycine at AA_{ox}^{1}

	nercially ailable NO ₂ NaHCO ₃ O aq THF AA ² O ₂ N AA ² 2-15	Ra-Ni H₂ ➤	AA) R ¹ N 17-30	AA^2 AA^2 A A A A A O O
entry	AA ² : -N OnPr	yield 2-15	R1	yield 17-30
1	$R^2 = H(2)$	59%	Boc	17 62%
2	R ² = Me (3)	74%	Boc	18 76%
3	$R^2 = i Pr (4)$	72%	Boc	19 85%
4	$R^2 = CH_2 Pr (5)$	52%	Boc	20 78%
5	$R^2 = CH_2C_6H_5$ (6)	95%	Boc	21 81%
6	$R^2 = CH_2C_6H_4$ -p-O-t-Bu (7)	71%	Cbz	22 82%
7	$R^2 = CH_2OCMe_3 (8)$	81%	Cbz	23 76%
8	$R^2 = (CH_2)_2 CO_2 t$ -Bu (9)	87%	Cbz	24 63%
9	R ² = CH ₂ CONHTrt (10)	73%	Cbz	25 72%
10	$R^2 = (CH_2)_4 NHBoc (11)$	66%	Cbz	26 57%
11	R ² = (CH ₂) ₂ SMe (12)	98%	Boc	27 35%
12	³ 2 ² √ N (13)	60%	Cbz	28 49%
13	Boc (14)	76%	Cbz	29 69%
14	(15)	84%	Вос	30 76%
10.000 (10.00) 10.000	1, NaHCO ₃ O Phe-OnPr aq THF Leu-Phe- NO ₂ 16	Ra- H		u-Phe-OnPr 32
3	10 10 2 16			32 wo steps)

Ala-OnPr in DMSO at 23 °C resulted in clean 1,4-addition to afford 3 in 74% yield (entry 2). This reaction proved successful with other α amino esters, with products resulting from the addition of glycine, L-leucine, L-valine, L-proline, and L-phenylalanine formed in 52%–95% yield. The mild reaction conditions were compatible with many of the standard side-chain protecting groups used in modern solid-phase peptide syntheses. The reaction of *t*Bu-protected L-tyrosine, L-serine, L-glutamic acid, and trityl protected L-asparagine with 1 afforded nitro alkanes 7, 8, 9, and 10 in 71%–87% yield. N-Trityl protected L-histidine and Boc-L-tryptophan furnished products 13 and 14 in 60% and 76% yield, respectively. N-Boc-protected L-lysine gave the nitroalkane 11 in 66% yield, and the L-methionine-containing nitro alkane 12 was formed in 98% yield.

We next investigated NO_2 -group reduction and the protection of the resulting amine. Raney nickel proved to be the most practical reducing agent, leading to a procedure where reduction in the presence of either $(Boc)_2O$ or CbzOSu (aq

NaHCO₃ in 4:1 THF/H₂O) using 1 atm of H₂ consistently produced a protected amine in a single operation in good yield.^{8,9} This protocol has proven to be remarkably general and allows for the formation of enantiopure oxetanyl dipeptides using inexpensive amino esters from the chiral pool (Table 1). Simple alkyl-substituted Boc-protected dimers derived from glycine, L-alanine, L-leucine, L-valine, and L-phenylalanine are formed in high yield (Table 1, entries 1-5). Compounds bearing tBu ethers and esters (7-9), as well as trityl-protected amides 10 and Boc-protected amines 11, all generated products in 57%-82% yield (entries 6-9, 12). The derivatives of Lhistidine and L-tryptophan furnished 28 and 29 in 49 and a 69% overall yield, respectively. To accommodate sulfur-bearing side chains, zinc/HCl was selected as a reducing agent (27). Dipeptides were also substrates for this process, with H-Leu-Phe-OnPr (31, Table 1) affording 32 in 62% yield (two steps).

Preliminary results also showed that direct addition of unprotected amino acids to nitro-olefin 1 is possible (Table 2).

Table 2. Synthesis of Dipeptides with Oxetanyl Glycine at AA_{ox}^1

$\begin{array}{c} H_2 N \underbrace{CO_2 H}_{\hat{R}} & H_2 N \underbrace{CO_2 H}_{NaHCO_3} O_2 N' \\ aq THF \end{array}$	$\begin{array}{c} H \\ & CO_2 H \\ \hline \\ O \\ 33-36 \end{array} \begin{array}{c} H \\ CO_2 H \\ \hline \\ H \\ CbzC \\ O \\ Fmoc \end{array}$	
R	Ρ	yield (3 steps) (37-40)
R = CH ₂ -OtBu	Cbz	37 44%
$R = CH_2C_6H_4$ -p-OtBu	Cbz	38 41%
R =	Cbz	39 27%
R = <i>i</i> Pr	Fmoc	40 38%

Indeed, mixing a (orthogonally protected) free amino acid with 1 in THF/H₂O in the presence of NaHCO₃ afforded nitro-acid adducts **33–36**. Crude mixtures were subjected to reduction of the nitro group with Raney Nickel and H₂, followed by filtration and treatment with CbzCl or FmocOSu to afford N-protected amino acid dimers **37–40** in 27%–44% yield over three steps. This result constitutes, to the best of our knowledge, the first example of conjugate addition of unprotected amino acids to unsaturated nitro compounds, as well as a direct approach to dimers ready for further coupling.

Through minor modifications of this protocol, other oxetanyl amino acid residues were incorporated at the AA¹_{ox} position. The synthesis of these compounds is exemplified in Table 3. The sequence begins with the Et₃N-promoted addition of the nitro alkanes 41-45 to oxetan-3-one.¹⁰ After conversion of nitro alcohols obtained to the corresponding mesylates, in situ treatment with glycine propyl ester then afforded nitro alkanes 46-51, which were in turn transformed to oxetanyl dipeptides 52-57. The transient formation of tetrasubstituted nitro alkenes was advantageous because of their tendency otherwise to undergo cyclization to the corresponding isoxazole under basic conditions.¹¹ The sequence proved to be high-yielding and efficient with a variety of substituted nitro alkanes featuring the side chains of leucine (41), O-tert-butyl tyrosine (42), glutamine tert-butyl ester (43), N-Boc lysine (44), and Tstryptophan (45). This process entails six synthetic transformations and is carried out with purification of only one intermediate.

$\begin{array}{c} O_2 N \\ R_1 \end{array} \begin{bmatrix} O_2 N \\ In \ situ \ situ \ situ \ situ \\ In \ situ \ si$		46-51	$X = NO_2$	ö
R ¹	R ²	yield (46-51)	Boc/ Cbz	yield (52-57)
R ¹ = CH ₂ - <i>i</i> Pr (41)	н	46 70%	Boc	52 65%
$R^1 = CH_2C_6H_4$ -p-OtBu (42)	н	47 73%	Cbz	53 43%
R ¹ = (CH ₂) ₂ CO ₂ tBu (43)	н	48 63%	Cbz	54 55%
R ¹ = (CH ₂) ₄ NHBoc (44)	н	49 89%	Cbz	55 64%
$R^{1} = \bigvee_{\substack{N \\ T_{S}}} (45)$	н	50 63%	Boc	56 28%
$R^1 = (CH_2)_4 NHBoc (44)$ (Cl	H ₂) ₄ NHBoc	51 81%	Cbz	57 55% (ca 1:1 dr)

Table 3. Synthesis of Oxetanyl Dipeptides with $AA^1 \neq Gly$

Using the strategy described above, the synthesis of complex oxetanyl peptide surrogates substituted at both $C\alpha$ and $C\alpha'$ positions was possible in a sequence requiring minimal chromatographic purification (52–57, Table 3). However, the ease of separation of the diastereomeric oxetanyl dipeptides generated was substrate-dependent. This constitutes a current limitation, and efforts are ongoing to devise a workable approach to this problem.

We next explored conditions for the incorporation of the oxetanyl dipeptide surrogates into a peptide chain (Figure 2).




Figure 2. Reactions of oxetanyl dipeptides.

We were delighted to observe that oxetanyl dipeptides were compatible with standard peptide coupling approaches. Thus, basic hydrolysis of the ester in **29** followed by workup and exposure of the unpurified acid to HBTU-mediated peptide coupling with H-Phe-OnPr·HCl afforded protected tripeptide **58** in 76% yield over two steps. It is important to note that **58** was obtained as a single diastereoisomer, showing that no racemization of AA^2 occurs during saponification. Chain elongation at the N-terminus of the oxetanyl dipeptide is also possible as shown in Figure 2 for **30** \rightarrow **59** and **24** \rightarrow **60**.

In conclusion, we have reported the design and synthesis of novel oxetanyl peptides, which expands the peptidomimetic structural space. We have developed a strategy for the incorporation of the oxetane fragment onto the peptide backbone that relies on standard peptide coupling techniques and that is amenable to the preparation of a range of amino acid dimer combinations. We have also shown that the embedded amino oxetanyl fragments are stable to a variety of acidic, basic, reductive, and oxidative reaction conditions. Further studies to establish the physicochemical and biological properties, as well as enzymatic stability, of these new building blocks are ongoing and will be reported in due course.

ASSOCIATED CONTENT

S Supporting Information

Experimental procedures and full spectroscopic data for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: carreira@org.chem.ethz.ch.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support from the NIH (USA) through a Ruth L. Kirschstein National Research Service Award to M.M. (GM090547), the Japan Society for Promotion of Science for a fellowship to R.Y., and ETH (TH 10-07-03) is acknowledged. SpiroChem AG is acknowledged for a generous gift of oxetan-3-one and nitromethyleneoxetane.

REFERENCES

(1) (a) Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Drug Discovery Today 2010, 15, 40–56. (b) Thaler, A. M. Chem. Eng. News 30 May 2011, 89 (22), 13–20.

(2) (a) Shen, W.-C. Drug Discovery Today 2003, 8, 607-608.
(b) Torchilin, V.; Lukyanov, A. N. Drug Discovery Today 2003, 8, 259-266.
(c) Pernot, M.; Vanderesse, R.; Frochot, C.; Guillemin, F.; Barberi-Heyob, M. Expert Opin. Drug Metab. Toxicol. 2011, 7, 793-802.

(3) (a) Vives, E.; Brodin, P.; Lebleu, B. J. Biol. Chem. **1997**, 272, 16010–16017. For reviews on cell-penetrating peptides, see: (b) Brasseur, R.; Divita, G. Biochim. Biophys. Acta **2010**, 1798, 2177–2181. (c) Fonseca, S. B.; Pereira, M. P.; Kelley, S. O. Adv. Drug Delivery Rev. **2009**, 61, 953–964.

(4) Search performed in March 2013: Thomson-Reuters Integrity.

(5) For selected reviews, see: (a) Foldamers: Structure, Properties and Applications; Hecht, S., Huc, I., Eds.; Wiley-VCH: Weinheim, 2007.
(b) Peptidomimetics Protocols; Kazmierski, W. M., Ed.; Humana Press Inc.: Totowa, NJ, 1999. (c) Ko, E.; Liu, J.; Burgess, K. Chem. Soc. Rev. 2011, 40, 4411-4421. (d) Seebach, D.; Gardiner, J. Acc. Chem. Res. 2008, 41, 1366-1375. (e) Smith, A.; Charnley, A.; Hirschmann, R. Chem. Rev. 2011, 44, 180-193. (f) Cheng, R.; Gellman, S.; Degrado, W. Chem. Rev. 2001, 101, 3219-3232. (g) Davis, J.; Tsou, L.; Hamilton, A. D. Chem. Soc. Rev. 2007, 36, 326-334. (h) Yin, H.; Hamilton, A. D. Angew. Chem., Int. Ed. 2005, 44, 4130-4163. (i) Weltler, M.; Barron, A. E. Biopolymers 2011, 96, 556-560. (j) Fowler, S.; Blackwell, H. E. Org. Biomol. Chem. 2009, 7, 1508-1524. Bukhard, J.; Tchitchanov, B.; Carreira, E. M. Angew. Chem., Int. Ed. 2011, 50, 5379-5382.

(6) (a) Researchers at Pfizer have carried out a comparative analysis of the metabolic stability of oxetanes versus other oxygen-containing rings; see: Stepan, A. F. J. Med. Chem. 2011, 54, 7772–7783. Researchers at Merck have also reported the addition nucleophiles to oxetan-3-tert-butylsulfinimine to access oxetanyl amines without substituents on the amino group, see: (b) Hamzik, P. J.; Brubaker, J. D. Org. Lett. 2010, 12, 1116–1119. See also: (c) Wuitschik, G.; Rogers-Evans, M.; Müller, K.; Fischer, H.; Wagner, B.; Schuler, F.; Polonchuk, L.; Carreira, E. M. Angew. Chem., Int. Ed. 2006, 45, 7736–7739. (d) Wuitschik, G.; Rogers-Evans, M.; Buckl, A.; Bernasconi, M.; Marki, M.; Godel, T.; Fischer, H.; Wagner, B.; Parrilla, I.; Schuler, F.;

Organic Letters

Schneider, J.; Alker, A.; Schweizer, W. B.; Müller, K.; Carreira, E. M. Angew. Chem., Int. Ed. 2008, 47, 4512–4515. (e) Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. J. Med. Chem. 2010, 53, 3227–3246. Azetidines: (f) Burkhard, J. A.; Wagner, B.; Fischer, H.; Schuler, F.; Müller, K.; Carreira, E. M. Angew. Chem., Int. Ed. 2010, 49, 3524–3527. (g) Burkhard, J. A.; Carreira, E. M. Org. Lett. 2008, 10, 3525–3526. (h) Burkhard, J. A.; Guérot, C.; Knust, H.; Rogers-Evans, M.; Carreira, E. M. Org. Lett. 2010, 12, 1944–1947.

(7) Benoiton, N. L. Chemistry of Peptide Synthesis; CRC Press: Boca Raton, FL, 2005.

(8) Tamura, O.; Yanagimichi, T.; Kobayashi, T.; Ishibashi, H. Org. Lett. 2001, 3, 2427.

(9) Interestingly the use of other esters (Me, Bn) proved inferior.

(10) Oxetan-3-one (CAS 6704-31-0) is commercially available on multikilogram scale from SpiroChem AG.

(11) Bukhard, J. A.; Tchitchanov, B.; Carreira, E. M. Angew. Chem., Int. Ed. 2011, 50, 5379-5382.